[{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hong Kong \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"University of Hong Kong \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Ribavirin","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Ribavirin","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Ribavirin","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ribavirin","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brii Biosciences \/ Vir Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Vir Biotechnology"},{"orgOrder":0,"company":"Melbourne Health","sponsor":"University of New South Wales | St Vincent's Hospital, Sydney | Western Hospital, Australia | Monash University | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Ribavirin","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Melbourne Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melbourne Health \/ University of New South Wales | St Vincent's Hospital, Sydney | Western Hospital, Australia | Monash University | F. Hoffmann-La Roche","highestDevelopmentStatusID":"11","companyTruncated":"Melbourne Health \/ University of New South Wales | St Vincent's Hospital, Sydney | Western Hospital, Australia | Monash University | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Kenneth Sherman","sponsor":"National Heart, Lung, and Blood Institute | Vertex Pharmaceuticals | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Ribavirin","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Kenneth Sherman","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kenneth Sherman \/ National Heart, Lung, and Blood Institute | Vertex Pharmaceuticals | Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Kenneth Sherman \/ National Heart, Lung, and Blood Institute | Vertex Pharmaceuticals | Genentech"},{"orgOrder":0,"company":"Irrua Specialist Teaching Hospital","sponsor":"Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NIGERIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Irrua Specialist Teaching Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irrua Specialist Teaching Hospital \/ Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme","highestDevelopmentStatusID":"9","companyTruncated":"Irrua Specialist Teaching Hospital \/ Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme"},{"orgOrder":0,"company":"Children's Hospital of Fudan University","sponsor":"Weihai Rensheng Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Children's Hospital of Fudan University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Fudan University \/ Weihai Rensheng Pharmacy","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital of Fudan University \/ Weihai Rensheng Pharmacy"},{"orgOrder":0,"company":"G\u00f6teborg University","sponsor":"The Swedish Research Council | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"G\u00f6teborg University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G\u00f6teborg University \/ The Swedish Research Council | F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"G\u00f6teborg University \/ The Swedish Research Council | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioLineRx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BioLineRx \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"GSK | University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ GSK | University of Colorado, Denver","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ GSK | University of Colorado, Denver"},{"orgOrder":0,"company":"Liver Institute of Virginia","sponsor":"Merck & Co | Chronic Liver Disease Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Liver Institute of Virginia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liver Institute of Virginia \/ Merck & Co | Chronic Liver Disease Foundation","highestDevelopmentStatusID":"11","companyTruncated":"Liver Institute of Virginia \/ Merck & Co | Chronic Liver Disease Foundation"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Scientific and Technological Research Council of Turkey","sponsor":"Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Scientific and Technological Research Council of Turkey","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Scientific and Technological Research Council of Turkey \/ Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO","highestDevelopmentStatusID":"9","companyTruncated":"Scientific and Technological Research Council of Turkey \/ Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO"}]
Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3557
Sponsor :
Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | Médecins Sans Frontières Belgium | Alex Ekwueme
Details :
Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Lassa Fever.
Sponsor :
Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | Médecins Sans Frontières Belgium | Alex Ekwueme
Details :
Peginterferon is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis B, Chronic.
Details :
Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Details :
Virazole (Ribavirin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Details :
Trial revealed that patients treated with triple drug combination (lopinavir–ritonavir and ribavirin) tested negative for COVID-19 five days earlier than those treated with lopinavir–ritonavir alone.
Details :
Virazole (Ribavirin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Details :
The company believes that since ribavirin is a synthetic nucleoside, It may work to stop viral replication and VIRAZOLE may be effective in reducing the severity of COVID-19 infection.
Details :
Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatitis C, Chronic.
Details :
Ribavirin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hand, Foot and Mouth Disease.
Reset All
